BioMarin Pharmaceutical(BMRN) - 2024 Q3 - Earnings Call Presentation

Financial Performance & Guidance - Third quarter VOXZOGO revenues increased by 54% year-over-year[6,7] - Third quarter Enzyme Therapies revenues grew 27% year-over-year[6,7] - The company raised full-year guidance at the midpoint: VOXZOGO revenues of $190 million (+54%), Enzyme Therapies revenues of $509 million (+27%), Non-GAAP Operating Margin of 27.7% (+11.5 ppts), and Non-GAAP Diluted Earnings per Share of $0.91 (+98%)[6] - The company reaffirmed long-term guidance, targeting ~$4 billion in revenue by 2027 and $1.25 billion+ in operating cash flow in 2027[8,15] - The company is targeting mid-teen revenue growth through 2034[15] Key Financial Metrics - Third quarter 2024 total revenue was $746 million, a 28% increase compared to the third quarter of 2023[11] - Third quarter 2024 Non-GAAP Operating Margin was 27.7%, compared to 16.2% in the third quarter of 2023[11] - Third quarter 2024 Non-GAAP Diluted EPS was $0.91, a 98% increase compared to $0.46 in the third quarter of 2023[11] - Year-to-date 2024 total revenue was $2.107 billion, a 19% increase compared to the same period in 2023[13] - Year-to-date 2024 Non-GAAP Operating Margin was 27.7%, compared to 20.1% for the same period in 2023[13] - Year-to-date 2024 Non-GAAP Diluted EPS was $2.60, a 63% increase compared to $1.60 for the same period in 2023[13]